El Futuro en el Tratamiento del Cáncer Renal - page 10

First line ongoing trials
https://clinicaltrials.gov/ct2/show/NCT02684006
Larkin J, et al. ESMO 2016
Javelin renal 101
Phase III
Avelumab + axitinib
10mg/kg IV every 2 weeks
+ 5mg PO BD
Sunitinib
50 mg/day 4/2
Primary endpoint: PFS
PD-L1 + VEGFR TK inhibition
R n=583